Citi Asserts Buy Rating on Summit Therapeutics Inc. (SMMT) on Pipeline Development

Summit Therapeutics Inc. (NASDAQ:SMMT) is one of the best biotech stocks to buy according to Wall Street analysts. On December 4, Citi analyst Yigal Nochomovitz reiterated a Buy rating on Summit Therapeutics Inc. (NASDAQ:SMMT) and set a $131.90 price target. Citi Asserts Buy Rating on Summit Therapeutics Inc. (SMMT) on Pipeline Development The positive stance follows the Jefferies London Healthcare Conference 2025, during which the company showcased its strategic advancements, including the development o ...